Premium
Preliminary results of 125 I interstitial brachytherapy for locally recurrent parotid gland cancer in previously irradiated patients
Author(s) -
Zheng Lei,
Zhang Jianguo,
Zhang Jie,
Song Tieli,
Huang Mingwei,
Yu Guangyan
Publication year - 2012
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.21955
Subject(s) - brachytherapy , medicine , parotid gland , nuclear medicine , radiation therapy , head and neck , stage (stratigraphy) , surgery , pathology , paleontology , biology
Background The purpose of this study was to analyze the treatment of recurrent parotid gland cancers with radioactive iodine ( 125 I) seed implantation. Methods Fifteen patients with recurrent previously irradiated parotid gland cancers were treated with postoperative 125 I seed implantation between April 2004 and June 2009. Local control, survival rates, and side effects were retrospectively reviewed. Results The 3‐year and 5‐year local control rates were 67% and 53.6%, and the overall survival rates were 76.2% and 66.7%, respectively. Four patients with House–Brackman (H–B) grade IV cancer recovered to grade II during follow‐up. Four patients (26.7%) developed grade IV skin ulceration. Two patients (13.3%) developed moderate fibrosis of the subcutaneous tissues, and 2 patients (13.3%) had hearing loss for 1 year after brachytherapy. Conclusion This study showed excellent local control and a good survival rate in patients who received 125 I brachytherapy. These findings should be interpreted cautiously due to the small number of patients and the relatively short follow‐up. © 2012 Wiley Periodicals, Inc. Head Neck , 2012